Question special

It was reassuring to see from the safety data that there weren't any signals for more serious adverse events with evolocumab than placebo. Did this trend apply across different levels of achieved LDL-C? For example, the lowest tertile vs. the highest tertile in the treatment group? Have any concerns arisen from observational studies of patients who have loss of function mutations in PCSK9?